View Rule
View EO 12866 Meetings | Printer-Friendly Version Download RIN Data in XML |
DOJ/DEA | RIN: 1117-AB75 | Publication ID: Fall 2022 |
Title: Schedules of Controlled Substances; Exempted Prescription Products | |
Abstract:
The Drug Enforcement Administration (DEA) proposes to revoke the exempted prescription product status for all butalbital products previously granted exemptions. DEA has observed a pattern of diversion, online distribution, and abuse of exempted butalbital products. In particular, DEA has observed exploitation of the exempted prescription product status of butalbital combination products to enable abuse. Therefore, DEA has concluded that these products do not meet the exemption criteria found in 21 U.S.C. 811(g)(3)(A). |
|
Agency: Department of Justice(DOJ) | Priority: Other Significant |
RIN Status: Previously published in the Unified Agenda | Agenda Stage of Rulemaking: Final Rule Stage |
Major: No | Unfunded Mandates: No |
CFR Citation: 21 CFR 1308.31 21 CFR 1308.32 | |
Legal Authority: 21 U.S.C. 811(g)(3) |
Legal Deadline:
None |
||||||||||||
Timetable:
|
Regulatory Flexibility Analysis Required: No | Government Levels Affected: None |
Small Entities Affected: Businesses | Federalism: No |
Included in the Regulatory Plan: No | |
RIN Data Printed in the FR: No | |
Agency Contact: Scott A. Brinks Section Chief, Regulatory Drafting and Support Section, Diversion Control Division Department of Justice Drug Enforcement Administration 8701 Morrissette Drive, Springfield, VA 22152 Phone:571 362-8209 Email: scott.a.brinks@dea.gov |